UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

December 1, 2017: By Joan McKenna

ExonateUK-based Exonate, an early stage company developing an eye drop treatment for wet AMD and diabetic macular edema, has formed a clinical advisory board of five ophthalmic experts.

Exonate’s preclinical compounds are designed to inhibit a protein kinase called SRPK1, which promotes production of vascular endothelial growth factor (VEGF), driving angiogenesis and retinal disease progression.

The five members of the advisory board are:

—Peter Adamson, PhD, head of ophthalmology research and development at Netherlands-based ProQR Therapeutics;

—Lloyd Paul Aiello, MD, PhD, professor of ophthalmology at Harvard Medical School and founding chair of the National Eye Institute Diabetic Retinopathy Clinical Research Network;

—Peter Campochiaro, MD, professor of ophthalmology at the Johns Hopkins Wilmer Eye Institute;

—Usha Chakravarthy, MD, professor of ophthalmology at Queen’s University Belfast, internationally known for research of the molecular mechanisms of AMD and diabetic retinopathy;

—Robyn Guymer, MBBS, PhD, professor of ophthalmology at Melbourne University, deputy director of the Centre for Eye Research Australia, and a senior retinal specialist at the Royal Victorian Eye and Ear Hospital.

In February, Exonate announced it had been awarded a £4.9 million seeding drug discovery award by the Wellcome Trust, a global charitable foundation, to continue development of its retinal candidates.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT